2 results
Approved WMOCompleted
Primary objectivesPhase I:To determine the recommended phase 2 dose (RP2D) of the dacomitinib-PD-0325901 combination in patients with KRASm NSCLC Phase II:To determine the progression free survival of the dacomitinib/PD-0325901 combination compared…
Approved WMOCompleted
Evaluate the long-term safety and effectiveness of two dose levels of orally administered BCX7353 in subjects with HAE